ExodusPoint Capital Management LP 13D and 13G filings for Keros Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-17 5:17 pm Sale | 2025-12-31 | 13G | KEROS THERAPEUTICS INC KROS | ExodusPoint Capital Management LP | 13,360 0.040% | -1,894,539 (-99.30%) | Filing |
| 2025-11-18 4:07 pm Purchase | 2025-11-10 | 13G | KEROS THERAPEUTICS INC KROS | ExodusPoint Capital Management LP | 1,907,899 6.300% | 1,907,899 (New Position) | Filing |